ThiPhiSA: New Pathways to Prevention From Community TB Screening in South Africa - Trial NCT06214910
Access comprehensive clinical trial information for NCT06214910 through Pure Global AI's free database. This Phase 4 trial is sponsored by University of Washington and is currently Recruiting. The study focuses on Tuberculosis. Target enrollment is 525 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
TB preventive therapy (TPT) - 3 months weekly isoniazid plus rifapentine (3HP)
Interventional
drug
Sponsor & Location
University of Washington
Timeline & Enrollment
Phase 4
Feb 20, 2024
Dec 31, 2026
Primary Outcome
Completion of a course of TB preventive therapy (TPT)
Summary
This study will compare community-delivered, multi-month dispensing of tuberculosis
 preventive therapy (TPT) to standard-of-care clinic-based TPT delivery in a population of
 South African adults who are recommended to receive TB preventive therapy.
 
 We hypothesize that persons receiving multi-month dispensing of TPT in the community will
 have a higher rate of TPT completion at 3 months than persons receiving TPT via standard of
 care with monthly clinic-based refills.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06214910
Non-Device Trial